The FDA has approved a tablet form of Livmarli (maralixibat) for cholestatic pruritus in patients with Alagille syndrome and progressive familial intrahepatic cholestasis.

The FDA has accepted for Priority Review the sBLA for aflibercept injection 8mg for the treatment of macular edema following RVO and for monthly dosing in approved indications.